ASHBURN, Virginia, August 28, 2026, 07:51 (EDT) — Shares in Quoin rose 41.8% after the company reported QRX003 achieved its primary endpoint, while a $50 million fundraising is anticipated.
- Quoin shares climbed 41.8% to $7.31 ahead of the market open.
- The interim primary endpoint was reached by four out of six QRX003 patients.
- The company raised $30.8 million in upfront funds via a private placement.
- The number of new ADSs may more than triple the current outstanding share count.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) stock surged 41.8% in premarket trading on Friday. Interim results for QRX003 reached a pre-defined statistical benchmark.
The surge increased implied equity value by approximately $4.3 million. However, it raised a broader issue: what portion of the clinical upside will current shareholders keep following financing?
Quoin plans to sell 6.31 million American Depositary Shares or pre-funded warrants, boosting the total from 2.01 million ADSs previously in circulation before this deal.
| Financing measure | Amount | Investor implication |
|---|---|---|
| Upfront capital | $30.8 million | Roughly 3.0 times the previous market value |
| Initial ADSs or equivalents | 6.31 million | Represents about 3.14 times the existing ADSs |
| Placement price | $4.88 | 33% under the $7.31 premarket quote |
| Ordinary warrants | 3.15 million | May result in further dilution |
| Warrant exercise price | $6.10 | 17% lower than the premarket quote |
| Total potential proceeds | $50.0 million | Runway extends into 2H 2029 |
The offering price is set at $4.88 for each ADS and warrant, marking a 33% discount to the $7.31 price quoted before market open.
Investors have the option to exercise 3.15 million more warrants priced at $6.10 each. If all warrants are exercised, it would generate an extra $19.2 million financing terms.
Current ADSs would account for about 24% of the total following the placement. This figure would drop to approximately 18% if all warrants are exercised, not including other securities.
The capital adjustment extends Quoin’s financial runway. Management anticipates that overall proceeds will support operations through the latter part of 2029.
Data showed that among six participants who finished a 12-week course, four recorded at least a one-grade improvement in Investigator Global Assessment.
The 66.7% response achieved the modified primary benchmark. The stated p-value stood at 0.0087 compared with the alpha level of 0.0215 interim results.
The key global-impression endpoint also met significance, showing a mean change of minus 1.5 and a p-value of 0.007.
Each of the three patients experiencing moderate-to-severe itching at baseline saw their symptoms improve by a minimum of three grades. Quoin said there were no serious adverse events related to the treatment.
The data is still initial. The six patients account for under one-third of the intended evaluable group of 20.
Recruitment is anticipated to conclude by the end of the year. Comprehensive Phase 2/3 topline results are slated for release in the second quarter of 2027.
Quoin reported cash and investments totaling $10.8 million as of June 30. The company posted a second-quarter net loss of $5.37 million, up from $3.70 million in the prior period quarterly results.
At 07:34 EDT, the stock was priced at $7.31 with 6.87 million shares traded in premarket activity. The previous session closed at $5.16 market quote.
Risks: The trial is open-label and involves a limited number of participants. Outcomes from future patients could vary, regulators might demand additional data, and further funding could significantly dilute current shareholders.
The investor choice stands out as particularly straightforward. Injecting new capital reduces immediate funding concerns, but the issued securities shift a significant portion of potential clinical gains.
